LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Lista de Ações・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Fechado

SetorSaúde

0.31 -8.82

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.31

Máximo

0.34

Indicadores-chave
By Trading Economics
Rendimento	-15M -35M
Vendas	-18M 581K
Margem de lucro	-6,012.048
Funcionários	183
EBITDA	-15M -33M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+1614.29% upside

Dividendos
By Dow Jones
Próximos Ganhos	30 de mar. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-50M 125M
Abertura anterior	9.13
Fecho anterior	0.31

Sentimento de Notícias

By Acuity

67%

33%

302 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

0.5207 / 0.7223 Suporte e Resistência

Sangamo Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mar. de 2026, 17:33 UTC

Notícias Principais

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 de mar. de 2026, 17:00 UTC

Notícias Principais

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 de mar. de 2026, 16:03 UTC

Notícias Principais

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 de mar. de 2026, 14:50 UTC

Grandes Movimentos do Mercado

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 de mar. de 2026, 14:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 de mar. de 2026, 14:29 UTC

Notícias Principais

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 de mar. de 2026, 14:16 UTC

Notícias Principais

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 19:16 UTC

Conversa de Mercado

Notícias Principais

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 de mar. de 2026, 19:07 UTC

Conversa de Mercado

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 de mar. de 2026, 19:04 UTC

Conversa de Mercado

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 de mar. de 2026, 19:03 UTC

Conversa de Mercado

Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 19:02 UTC

Conversa de Mercado

Notícias Principais

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 de mar. de 2026, 18:12 UTC

Conversa de Mercado

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 de mar. de 2026, 17:36 UTC

Notícias Principais

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 de mar. de 2026, 17:34 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 de mar. de 2026, 17:29 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 de mar. de 2026, 16:38 UTC

Conversa de Mercado

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 de mar. de 2026, 16:32 UTC

Conversa de Mercado

Notícias Principais

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 de mar. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 15:43 UTC

Conversa de Mercado

Notícias Principais

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 de mar. de 2026, 14:36 UTC

Conversa de Mercado

Notícias Principais

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 de mar. de 2026, 14:26 UTC

Conversa de Mercado

Notícias Principais

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 de mar. de 2026, 14:14 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 14:14 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

Comparação entre Pares

Variação de preço

Sangamo Therapeutics Inc Previsão

Preço-alvo

By TipRanks

1614.29% parte superior

Previsão para 12 meses

Média 6 USD 1614.29%

Máximo 10 USD

Mínimo 2 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Sangamo Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Sangamo Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.5207 / 0.7223Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentimento

By Acuity

302 / 349 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.